Published in PLoS One on June 12, 2013
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05
Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res (1982) 11.72
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell (2003) 5.66
TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. EMBO J (2005) 4.51
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell (2008) 2.66
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci (2002) 2.10
Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology (1999) 2.05
Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci (2010) 2.04
harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J (1997) 1.97
The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene (2011) 1.95
Liver-specific activities of FGF19 require Klotho beta. J Biol Chem (2007) 1.90
Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res (2010) 1.77
YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis (2010) 1.75
The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ (2006) 1.72
YAP: at the crossroad between transformation and tumor suppression. Cell Cycle (2009) 1.67
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget (2012) 1.55
Signaling by IL-1beta+IFN-gamma and ER stress converge on DP5/Hrk activation: a novel mechanism for pancreatic beta-cell apoptosis. Cell Death Differ (2009) 1.47
Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology (2002) 1.35
Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol (2006) 1.31
Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer (2012) 1.19
Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol (2009) 1.16
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One (2012) 1.15
Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol (1989) 1.04
Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle (2012) 1.01
Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol (2005) 1.00
Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci (2004) 0.99
Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation. Int J Mol Med (2004) 0.99
Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle (2010) 0.95
The role of HRK gene in human cancer. Oncogene (2008) 0.93
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biol Ther (2007) 0.92
Activation of multiple cancer pathways and tumor maintenance function of the 3q amplified oncogene FNDC3B. Cell Cycle (2012) 0.92
Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol (2011) 0.89
The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. Cancer Lett (2012) 0.89
Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study . Ann N Y Acad Sci (2009) 0.89
Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis. J Gastrointest Surg (2003) 0.88
Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. Ann N Y Acad Sci (2009) 0.88
Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system. PLoS One (2012) 0.85
Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Mol Cancer (2012) 0.85
Synergistic silencing by promoter methylation and reduced AP-2α transactivation of the proapoptotic HRK gene confers apoptosis resistance and enhanced tumor growth. Am J Pathol (2012) 0.85
COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. OMICS (2011) 0.82
Downregulation of wild-type beta-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 cells: a possible role in the growth-regulatory effects of the cytokine? Eur J Cancer (2001) 0.81
The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int J Mol Med (2006) 0.80
Multifunctional protein APPL2 contributes to survival of human glioma cells. Mol Oncol (2012) 0.80
Renal gene expression profiling using kinin B1 and B2 receptor knockout mice reveals comparable modulation of functionally related genes. Biol Chem (2006) 0.79
E2F-1- and E2Ftr-mediated apoptosis: the role of DREAM and HRK. J Cell Mol Med (2012) 0.78
YAP1--friend and foe. Cell Cycle (2010) 0.78
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology (2008) 2.28
PAP/HIP protein is an obesogenic factor. J Cell Physiol (2014) 1.98
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol (2003) 1.91
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Senescence-associated exosome release from human prostate cancer cells. Cancer Res (2008) 1.78
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget (2010) 1.64
GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget (2014) 1.56
Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res (2003) 1.55
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget (2012) 1.55
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle (2009) 1.54
Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem (2003) 1.50
Inhibition of the CaM-kinases augments cell death in response to oxygen radicals and oxygen radical inducing cancer therapies in MCF-7 human breast cancer cells. Cancer Biol Ther (2006) 1.48
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res (2010) 1.46
EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol (2003) 1.43
B-raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells. Cell Cycle (2004) 1.43
Akt as a therapeutic target in cancer. Expert Opin Ther Targets (2008) 1.41
Hepatocellular carcinoma: comparison of two different periods at the same center. Eur J Intern Med (2010) 1.41
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol (2011) 1.40
Celiac disease in the developing countries: a new and challenging public health problem. World J Gastroenterol (2007) 1.40
Redox regulation of the calcium/calmodulin-dependent protein kinases. J Biol Chem (2004) 1.39
The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle (2009) 1.38
Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs (2009) 1.36
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget (2012) 1.34
Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol (2011) 1.34
Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol (2006) 1.31
Melanoma: molecular pathogenesis and emerging target therapies (Review). Int J Oncol (2009) 1.31
Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle (2004) 1.30
The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta (2010) 1.30
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res (2009) 1.29
Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res (2004) 1.28
Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle (2008) 1.25
YY1 is regulated by O-linked N-acetylglucosaminylation (O-glcNAcylation). J Biol Chem (2003) 1.25
Comparison of anti-transglutaminase ELISAs and an anti-endomysial antibody assay in the diagnosis of celiac disease: a prospective study. Clin Chem (2002) 1.24
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget (2012) 1.23
Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene (2003) 1.21
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle (2010) 1.18
Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin. Cancer Biol Ther (2005) 1.17
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle (2011) 1.17
Substance P induces TNF-alpha and IL-6 production through NF kappa B in peritoneal mast cells. Biochim Biophys Acta (2003) 1.16
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget (2011) 1.16
Emerging MEK inhibitors. Expert Opin Emerg Drugs (2010) 1.16
Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res (2003) 1.15
Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget (2014) 1.14
Histone deacetylase (HDAC) activity is critical for embryonic kidney gene expression, growth, and differentiation. J Biol Chem (2011) 1.14
Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics (2008) 1.13
Integrin signaling links protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene (2004) 1.13
Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. Cell Cycle (2012) 1.11
Solubility and bioactivity of the Pseudomonas quinolone signal are increased by a Pseudomonas aeruginosa-produced surfactant. Infect Immun (2005) 1.11
Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol (2006) 1.11
Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle (2005) 1.10
Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. Ann N Y Acad Sci (2004) 1.09
Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol (2011) 1.08
The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle (2013) 1.08
Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat (2007) 1.08
A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle (2007) 1.08
Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol (2006) 1.07
Advances in targeting signal transduction pathways. Oncotarget (2012) 1.06
Elevated blood Hsp60, its structural similarities and cross-reactivity with thyroid molecules, and its presence on the plasma membrane of oncocytes point to the chaperonin as an immunopathogenic factor in Hashimoto's thyroiditis. Cell Stress Chaperones (2013) 1.05
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J Hepatol (2005) 1.04
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res (2008) 1.04
Calcium/calmodulin-dependent kinase I and calcium/calmodulin-dependent kinase kinase participate in the control of cell cycle progression in MCF-7 human breast cancer cells. Cancer Res (2005) 1.04
The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy. Oncotarget (2013) 1.03
The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets (2004) 1.03
Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. Oncotarget (2012) 1.02
The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it? Expert Opin Ther Targets (2005) 1.02
Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle (2012) 1.01
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol (2014) 1.00
Potential use of rapamycin in HIV infection. Br J Clin Pharmacol (2010) 1.00
Serum low density lipoprotein subclasses in asthma. Respir Med (2013) 1.00
Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol (2005) 1.00
Signaling through 3',5'-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer. J Clin Endocrinol Metab (2004) 0.99
Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci (2004) 0.99
Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation. Int J Mol Med (2004) 0.99
Increased protein expression of the PTEN tumor suppressor in the presence of constitutively active Notch-1. Cell Cycle (2005) 0.98
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget (2014) 0.98
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. Histol Histopathol (2010) 0.97
EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle (2006) 0.97
Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. World J Gastroenterol (2013) 0.96
PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer. BMC Cancer (2007) 0.96
Participation of the calcium/calmodulin-dependent kinases in hydrogen peroxide-induced Ikappa B phosphorylation in human T lymphocytes. J Biol Chem (2002) 0.96
Autoimmune enteropathy and colitis in an adult patient. Dig Dis Sci (2003) 0.96